Here are five things to know:
1. Three brokers rated the company a “Buy” and one rated a “Sell,” bringing the consensus to “Buy”
2. The company’s average 12-month price among covering brokers is $29.33 in the last year.
3. Piper Jaffray analysts reiterated an “overweight” rating and set a price target of $29 in a note on Friday.
4. Zacks analysts downgraded K2M shares at the end of May from “hold” to “sell.”
5. The company traded up today, hitting $24.74 and has a market cap of $981.06 million.
More articles on orthopedic devices:
BioMedical Enterprises launches nitinol bone fixation implant
DePuy Orthopaedics issues Class 2 recall for femoral implants
Boston Scientific launches Precision Novi SCS in Europe
